Company / R&D Expense
Dare Bioscience, Inc. R&D Expense History
FY2014-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$14.3M
FY2025
5-year range
$11.8M / $30.6M
FY2021-FY2025
Trend
-33.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
R&D Expense has declined for 3 consecutive years, from $31M in FY2022 to $14M in FY2025.
Based on SEC 10-K filings.
$14M in FY2025 with a 10-year CAGR of +4.0%.
Declined from $30M to $14M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -22.4%
- 5-Year CAGR
- -
- 10-Year CAGR
- +4.0%
Key checks
Key Insights
- Dare Bioscience, Inc.'s r&d expense has declined for 3 consecutive years.
- 3-year CAGR of -22.4%, indicating a declining trend.
- In FY2025, r&d expense decreased 33.6% year-over-year.
- Peak r&d expense was recorded in FY2022.
Company context
Key Data Points
- Altman Z-Score -2.23 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $14.3M | -33.6% |
| FY2024 | $21.5M | -28.3% |
| FY2023 | $30.0M | -1.9% |
| FY2022 | $30.6M | +160.1% |
| FY2016 | $11.8M | +21.4% |
| FY2015 | $9.7M | -38.6% |
| FY2014 | $15.8M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026